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Editorial on the Research Topic
Addressing Roles for Glycans in Immunology Using Chemical Biology
INTRODUCTION TO CHEMICAL GLYCOIMMUNOLOGY
Advances in genetic techniques have enabled the identification of disease-susceptibility genes and
the development of experimental models for mechanistic studies. However, this progress has only
partially translated into new therapies, highlighting the relevance of both epigenetic control of gene
expression and post-translational modifications as control points in the transition from genotype to
phenotype. The cell surface provides a tightly-regulated temporal and spatial signature containing
crucial biological information, and much of its dynamic response to environmental factors remains
to be explored.
Glycoconjugates, macromolecules containing carbohydrates (glycans) linked to proteins or
lipids, are a central component of the cell surface. These structurally diverse biomolecules expose
their carbohydrate portion outside the cell, and in doing so, are essential in storing and transmitting
information and regulating cell-cell interactions. One of the many fields where glycans have
arisen as key communicators is immunology, as they mediate diverse immunological functions
(Zhou et al., 2018). The complex mechanisms involved in the biosynthesis and assembly of
glycans is a non-template driven manner, which results in a high, natural heterogeneity that is
key to adapting cellular responses. However, structural characterization of these glycans and the
functional interpretation of the array of carbohydrates on a cell surface, generally referred to as the
glycome, remains an analytical challenge for chemists.
Since the glycome is unique to each cell type and significantly different between organisms, “self ”
and “non-self ” signals are imbedded in the glycome (Varki, 2011). Moreover, glycans on immune
cells are involved in different processes such as cell differentiation, trafficking, and response to
pathogens (Varki, 2017). In this sense, glycan information is translated by glycan binding proteins
(GBPs), also called lectins. The abilities of these GBPs to modulate immune cell function is
intimately connected to their ability to differentiate glycan structures in a precise and effective
manner. Evolution of lectins has granted these proteins a selective recognition, which is influenced
not only by structure, but also by multivalency of their cognate glycan ligand, reflecting the
naturally crowded and heterogeneous state of the cell surface (Kaltner et al., 2019). Consequently,
chemistry has been crucial in untangling the roles of GBP-glycan interactions. Chemical tools and
approaches provide a powerful complementary approach that has greatly aided our understanding
of GBPs by designing inhibitors and synthetic ligands able to control immune cell function via
glycan recognition. Below, we discuss the 13 manuscripts within this series in the context of three
themes: GBPs, immunomodulation, and technological advances.
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TARGETING AND EXPLOITING GBPs
In mammals, immune cells are modulated by three major GBP
families: C-type lectins (Brown et al., 2018), Galectins (Cerliani
et al., 2017), and Siglecs (Duan and Paulson, 2020; Laubli and
Varki, 2020). Galectins are a family of evolutionary-conserved,
soluble lectins involved in multiple immunoregulatory pathways.
Unraveling the molecular determinants of ligand recognition has
and will continue to provide a path toward lectin engineering
for improved function and efficient inhibition. This topic is
reviewed byModenutti et al., providing a synopsis of the available
tools for studying galectins and their structural characterization,
with emphasis on the role of water molecules in galectin-glycan
binding. An alternative for modulating immune responses is
using recombinant lectins to target cell surface glycans. Working
with an engineered galectin1-galectin3 tetramer, Farhadi et al.
investigated induction of apoptosis in cultured T cells. Through
amplifying and integrating galectin-1 and−3 activities, these
synthetic constructs provide new tools for understanding how
these lectins, and their glycan ligands, influence innate and
adaptive immunity. Beyond the human immune response, Vasta
et al. provide a review on simpler organisms lacking adaptive
immunity that also leverage galectins. Focusing on oysters and a
parasite called Perkinsus marinus, that can deplete oyster stocks,
the authors review recent evidence implicating galectin-like
proteins produced by the oysters as a defense mechanism against
the parasite. An intriguingmechanism is proposed whereby these
oyster-derived GBPs bind both “self ” and “non-self ” glycans
on host and pathogen to bring the parasite to the phagocytic
hemocytes of the host.
Even though lectin families are defined by their affinity
toward certain monosaccharides or oligosaccharide structures,
most GBPs have low monovalent affinities, which is greatly
enhanced through cell surface multivalency. Inspired by
this principle of avidity, Li et al. and Goyard et al. designed
synthetic multivalent glycoclusters to target GBPs on
mammalian immune cells or pathogens, respectively. In
the first manuscript, the focus is on DC-SIGN, a C-type
lectin on dendritic cells (Li et al.). A comprehensive 20-
member library of mannosides was synthesized based on 5
substructures of a high mannose N-glycan, each displayed
at four valencies, and the most multivalent (hexameric)
constructs showed the best binding to DC-SIGN. A TLR
agonist and peptide T cell epitope were conjugated to the
hexameric constructs and, surprisingly, their ability to induce
monocyte maturation and T cell activation did not directly
correlate with ligand potency. Accordingly, the avidity for
DC-SIGN may have other consequences, such as intracellular
routing and antigen presentation. In the second manuscript, a
synthetic strategy is presented to prepare heteroglycoclusters
designed to interact with LecA (galactose-binding lectin)
and LecB (fucose binding lectin) (Goyard et al.). These
lectins are virulence factors from Pseudomonas aeruginosa.
Working with cyclopeptide-based heteroglycoclusters, fucose,
mannose, and galactose can be co-presented to mimic the





Two major classes of glycoproteins are N-glycans and mucin-
type O-glycans (Moremen et al., 2012). Heavily O-glycosylated
mucins are an important component of the molecular shield
of gastrointestinal, respiratory, and reproductive epithelial
tissues. Pinzón Martín et al. reviewed the role of mucins
in immunomodulation from a chemical perspective, pointing
out the current challenges in their synthesis, expression, and
structural characterization as fundamental and necessary steps
toward understanding their clinical application. Glycoproteins
can also be used for antibody development of anti-carbohydrate
antibodies, which often requires the glycan to be chemically
conjugated to a carrier protein. Pillot et al. address an
important question, asking whether the protein conjugation
site matters. Working with the Pneumococcal surface adhesin
A protein, five mutants were engineered each with a single
cysteine at different distances from known T-helper epitopes. A
synthetic tetrasaccharide carbohydrate antigen, from the capsular
polysaccharide of S. pneumoniae, was conjugated to the mutants
via maleimide chemistry. The conjugation site furthest from
the T-helper epitopes generated the highest anti-carbohydrate
antibody titers, indicating that the site of conjugation does
matter, which has important implications for the design of
conjugate vaccines.
Glycolipids are another major class of glycoconjugates. Work
by Lai et al. and Howlader et al. demonstrate applications of
synthetically-prepared glycolipids and inhibitors of glycolipid-
acting enzymes, respectively. Invariant NKT (iNKT) cells
recognize glycolipids presented by CD1d (Rossjohn et al., 2012),
and Lai et al. explore how iNKT cells respond to α-Lactosyl
Ceramide (α-LacCer) relative to the commonly used α-Galactosyl
Ceramide (α-GalCer). α-LacCer was synthesized and found to
stimulate much weaker iNKT cell responses compared to α-
GalCer. Consequently, α-LacCer suppressed iNKT responses
to α-GalCer, which the authors use as a means of modulate
iNKT responses and disease in the context of several iNKT-
dependent injury mouse models. In the second manuscript, the
ability of catabolic enzymes (sialidases) to remodel glycolipids
were examined in the context of leukocyte adhesion. Using a
neuraminidase-3 (Neu3) inhibitor, Howlader et al. report that
interactions between the integrin LFA1 and ICAM, a key step
in leukocyte adhesion and migration to inflammatory sites, is
altered. Modulating Neu3 activity not only affected cell glycolipid
composition, but also altered LFA1 sialylation, expression on the




Chemistry has been instrumental in generating libraries of
natural oligosaccharides. Such libraries have enabled the study
of GBP specificity and glycoprofiling of diverse, complex
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biological samples, such as human plasma to investigate aberrant
glycosylation as a source of disease biomarkers. Specifically,
Glycan libraries continue to be strongly leveraged for use in
glycan microarrays. A review of glycan microarrays is presented
by Gao et al., which begins by exploring chemical linking
strategies used for immobilizing glycans to solid supports. An
overview is presented on applications of glycan microarrays for
studying the glycan binding specificity of Siglecs and Galectins,
entry receptors for pathogens, and naturally occurring anti-
glycan antibodies in humans (Gao et al.). Next generation
approaches, such as those using DNA-encoding and cell-based
approaches, are also discussed.
The natural heterogeneity of glycans has, for many years,
delayed their detailed structural characterization and impaired
a thorough understanding of their biological relevance.
Three articles deal with the analytical challenge of glycan
characterization from different perspectives (Lippold et al.;
Rebello et al.; de Haas et al.). de Haas et al. review the advances
in understanding the role of N-glycans on cell surface immune
receptors. Here, available methodologies are discussed in relation
to their potential to study this post-translational modification on
processes such as pathogen recognition, antigen presentation,
and immune signaling. Considering that monoclonal antibodies
as therapeutics have revolutionized clinical approaches to treat
many diseases, and the fact that their glycosylation can regulate
their therapeutic efficacy through modulating their interactions
with antibody receptors, glycoprofiling of antibodies has reached
the spotlight in recent years (Mimura et al., 2018). Lippold
et al. present the development of an affinity chromatography-
mass spectrometry approach to understand the relevance of
heterogeneous glycosylation of monoclonal antibodies. Their
methodology focuses in the heterogeneous glycosylation of mAbs
and its interaction with FCgIIIA, which is critically important
in antibody-dependent cellular cytotoxicity. This functional
separation was applied to Cetuximab as a case study, since this
antibody contains a glycosylation site in both the Fc and Fab
regions. Finally, and beyond biotherapeutics, the human plasma
N-glycome has arisen as a source of biomarkers for different
pathologies. Rebello et al. present a mass spectrometry assay
for the relative quantitation of antennary fucosylation in total
plasma N-glycome. The utility of this application was highlighted
by its ability to detect and quantify antennary fucosylation in the
plasma of colorectal cancer patients.
FUTURE PERSPECTIVES
This collection of articles highlights the relevance of
chemical approaches for studying glyco-related immune
pathways, exemplified with probes to target GBPs, structure–
function relationships, and new analytical techniques. A
close collaboration and interplay between chemists and
immunologists have and will continue to lead to new
breakthrough in the roles of glycosylation in immunity.
Indeed, outcomes of this interdisciplinary strategy is facilitating
and will certainly accelerate vaccine design, identification
of new biomarkers and moreover, precise modulation of
biotherapeutic activities.
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